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The emergence and spread of drug resistant pathogens and our
inability to develop new antimicrobials to combat resistance (pheno-
typic and genetic) has motivated scientists to consider non-traditional
targets where human homologs clearly exist. Cellular bioenergetics is an
area showing promise for the development of new antimicrobials, but
the success of this area will only emerge by understanding the role of
these energetic processes (e.g. respiration and oxidative phosphoryla-
tion) under conditions that prevail in host tissues. In this session, wewill
examine the recent developments in the ﬁeld suggesting cellular
energetics as a target space for the development of new antimicrobials.
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Energy metabolism has emerged as a new target-pathway for
development of new anti-tubercular drugs [1]. We investigated a
selective ATP synthase inhibitor, bedaquiline (TMC207)[2-4] and
its target, mycobacterial ATP synthase [5]. In this poster we present
insight into the chemical biology of this new drug/target system,
elucidating the bacterial metabolic response upon bedaquiline treat-
ment. BDQ treatment of mycobacteria triggered upregulation of
pathways involved in ATP production, including enzymes of the
glycolytic pathway, the pyruvate dehydrogenase complex and the
tricarboxylic acid cycle, as well as ATP synthase and the cytochrome bd
oxidase [6]. In contrast, major biosynthetic pathways were downregu-
lated upon BDQ treatment, including ribosomal protein synthesis, DNA
biosynthesis and synthesis of mycolic acids, a key component of the
mycobacterial cell envelope [6]. These changes in the mycobacterial
proteome reﬂect a general strategy employed by mycobacteria for
preserving ATP pools, minimizing consumption of cellular ATP and
utilizing alternative ATP-generating pathways. [1] D. Bald, A. Koul.
Advances and strategies in discovery of new antibacterials for combating
metabolically resting bacteria. Drug Discov. Today 18 (2013) 250-255.
[2] K. Andries, P. Verhasselt, J. Guillemont, et al. A diarylquinoline drug
active on the ATP synthase of Mycobacterium tuberculosis. Science 307
(2005) 223-227. [3] A. Koul, N. Dendouga, K. Vergauwen et al.
Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat.
Chem. Biol. 3 (2007) 323-324. [4] A.C. Haagsma, I. Podasca, A. et al.
Probing the interaction of the diarylquinoline TMC207 with its target
mycobacterial ATP synthase. PLoS One 6 (2011) e23575 [5] A.C.
Haagsma, N.N. Driessen, M.M. Hahn et al. ATP synthase in slow- and
fast-growing mycobacteria is active in ATP synthesis and blocked in ATP
hydrolysis direction. FEMSMicrobiol. Lett. 313 (2010) 68-74. [6] A. Koul,
L. Vrancks, N. Dhar et al. Delayed bactericidal response ofMycobacterium
tuberculosis to bedaquiline involves remodeling of bacterialmetabolism.
Nat. Commun. 5 (2014) 3369.
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With the increasing occurrence of drug resistance in diseases
including tuberculosis (TB) new drug targets, new lead compounds,
and new antimicrobial strategies are all of interest. Recently TMC207/
Bedaquiline, a compound that inhibits ATP synthesis in mycobacteria,
was approved for use in patients withmultidrug-resistant or extensively
drug resistant-TB suggesting that oxidative phosphorylation is a
vulnerable drug target in mycobacteria. This view is supported by
studies from our laboratory and others that suggest menaquinone
synthesis (required for electron transport inmycobacteria) is also a valid
drug target. Recent data indicates that saturation of a single isoprene unit
in the menaquinone of Mycobacterium tuberculosis represents a novel
virulence factor for this pathogen. Rv0561c, annotated as a possible
oxidoreductase, in the Mycobacterium tuberculosis H37Rv genome and
MSMEG1132 in Mycobacterium smegmatis are shown to encode
enzymes that increase the mass of menaquinone by two AMU. Mass
spectral analysis unambiguously demonstrated that these enzymes did
not reduce the aromatic ring moieties, but increased the mass of the
isoprenyl side chains by reducing one double bond. Thus, this previously
undescribed reductase catalyzes the ﬁnal step in the synthesis of the
predominant form of menaquinone found in mycobacteria and, presum-
ably, other Gram-positive bacteria that synthesize partially saturated
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